# How Long Retatrutide Takes to Work in Studies > How long does retatrutide take to work? In Phase 2 obesity trials, appetite changes were reported within 8 weeks; -24.2% mean weight loss was measured at 48 weeks. Timeline from the published research. What the Phase 2 trial data and participant reports show about the onset and trajectory of effects. ## What the timeline looked like in Phase 2 How long does retatrutide take to work in studies? The short version: appetite and eating-behavior changes were reported within the first 8 weeks in Phase 2 trial interviews; statistically significant weight reductions were evident at earlier timepoints; and the largest measured effect — a mean −24.2% body weight reduction at 12 mg — was reached at 48 weeks in the Phase 2 obesity trial [1]. Weight loss continued throughout the 48-week period without plateauing, which distinguishes the retatrutide trajectory from some earlier incretin-class agents where loss flattened after 16–24 weeks. This is a research digest covering published trial data. All timeline figures are from Phase 2 controlled trials conducted by Eli Lilly under clinical oversight — not from anecdotal community reports. ## Early weeks: eating behavior changes first The qualitative exit-interview study with 40 Phase 2 trial participants found that 31 of 36 retatrutide-treated subjects reported changes in eating behavior within the first 8 weeks of treatment [10]. The changes described were: reduced hunger frequency, greater satiety after smaller meals, reduced portion sizes, altered food preferences, and a greater sense of control over eating behavior. These are patient-reported outcomes from the interview study, not blinded measurements — but they are clinical data from a published study, not community anecdote. The appetite-behavior changes typically precede measurable weight loss on the scale, because the mechanism works through reducing caloric intake rather than directly mobilizing stored fat — weight on the scale reflects accumulated net calorie balance over weeks, not the day-to-day changes in hunger. The neurological component — GLP-1 receptor activation in reward and appetite circuits — may explain why appetite suppression is often described as qualitative and pervasive ("food noise going quiet") rather than simply feeling full [7]. ## Weeks 8-24: the primary trajectory The Phase 2 obesity trial used a 48-week timeline with pre-specified endpoints at multiple timepoints [1]. The dose-dependent weight-loss trajectory across all four active dose groups (1, 4, 8, and 12 mg) showed meaningful separation from placebo (which showed approximately −2.1% at 48 weeks) by early in the trial, with the trajectory continuing downward through week 48 without a clear plateau. The Phase 1b first-in-human study found a placebo-adjusted weight loss of −8.96 kg (90% CI −11.16 to −6.75 kg) at the highest dose group over just 12 weeks [4]. That figure illustrates the early-onset weight effect even at a 12-week endpoint — a meaningful signal in a population with type 2 diabetes and a shorter trial duration than the obesity Phase 2. In the diabetes Phase 2 trial, HbA1c (the three-month average blood-glucose marker) was measured at 24 weeks and showed a −2.02 percentage-point reduction at 12 mg [2]. Because HbA1c reflects a trailing three-month average, meaningful HbA1c reduction at 24 weeks implies glucose improvements that began in the earlier weeks of treatment. ## Weeks 24-48: continued loss, no plateau A notable feature of the Phase 2 obesity data is that weight loss did not appear to plateau through 48 weeks at the highest doses [1]. The 48-week endpoint (−24.2% at 12 mg) was the primary outcome; whether weight loss would have continued beyond 48 weeks, stabilized, or reversed is not answered by the Phase 2 data alone. Phase 3 TRIUMPH trials, with longer follow-up and larger samples, will address durability. For the liver-fat substudy, the reductions observed at 24 weeks (−82.4% at 12 mg) were sustained and slightly increased at 48 weeks (−86.0% at 12 mg) [5], suggesting that the liver-fat effect was durable through the trial window. A 2025 review synthesizes retatrutide's Phase 1/2 trajectory as a characteristic of the triple-agonist mechanism — particularly the glucagon-receptor contribution to energy expenditure, which adds a fat-burning drive that runs in parallel with appetite suppression rather than being limited by caloric restriction alone [6]. Whether this property accounts for the continued loss trajectory versus the plateau seen with some GLP-1 mono-agonists is an open research question. ## After stopping: durability is unknown Retatrutide's long-term durability after discontinuation is not established in the published literature. No published Phase 2 extension data from the off-treatment period are available for retatrutide as of mid-2026. Data from analogous GLP-1-class agents consistently show substantial weight regain after discontinuation — which is the basis for the ongoing concern in the research community about the open-ended nature of effective incretin therapy. Whether retatrutide's glucagon-receptor component, which drives metabolic adaptation (increased energy expenditure), confers any degree of sustained metabolic change after treatment ends is unknown. The Phase 3 TRIUMPH trials are designed with follow-up periods that may address this question, but results are pending. The uncertainty about durability is one of the major open questions in the retatrutide record and is listed in the safety cautions on [Retatrutide effects](/effects). --- An editorial reading of the Phase 1–3 retatrutide record — every figure walked back to its trial, with no clinic behind the reading room and nothing here prescribed or sold.